10% Owner Daniel Schneeberger Buys Over $1.1M in Rallybio Stock Amidst Post-Merger Termination Accumulation
RLYB has more than doubled off its 52-week low of $2.16 on light trading volume (0.2× avg).
Summary
A 10% owner of Rallybio Corp, Daniel Schneeberger, purchased over $1.1 million in common stock, continuing a pattern of insider accumulation after the company received a $50 million merger termination fee.
Key Events · Ownership and Investor Activity · RLYB
-
Significant Insider Purchase
Daniel Schneeberger, a 10% owner, acquired 79,559 shares of Rallybio Corp common stock for a total value of $1,112,977 through open market purchases between May 13 and May 15, 2026.
-
Continued Insider Accumulation
This purchase contributes to a recent trend of insider accumulation, with over $2.88 million in net open-market buys by insiders in the last 90 days, including a prior $2.18 million purchase by Schneeberger on May 7, 2026.
-
Post-Merger Termination Context
The buying activity follows the company's recent termination of a reverse merger agreement with Candid Therapeutics, which resulted in Rallybio receiving a $50 million termination fee, significantly boosting its cash reserves and extending its operational runway.
Analysis · RLYB · Life Sciences
Daniel Schneeberger, a 10% owner, made a substantial open market purchase of Rallybio Corp stock, adding over $1.1 million to his holdings. This follows a previous $2.18 million purchase by Schneeberger and occurs shortly after the company terminated a reverse merger agreement, receiving a $50 million termination fee. This significant cash infusion has extended the company's operational runway, and the continued insider buying suggests strong conviction in the company's prospects following these strategic shifts.
How filings like this one have moved
In the 30 days to Oct 15, 2026, 37.1% of the 974 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.64%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RLYB was trading at $14.30 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.8M. The 52-week trading range was $2.16 to $15.31. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.